GENOVIS AB SE-40
Research GENOVIS AB SE-40 (5GV) on Bullrun: valuation model: 40.7% overvalued, market cap EUR 110.59M, P/E 55.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker5GV
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Valuation signal40.7% overvalued
- Market capEUR 110.59M
- P/E55.8
- Financial periodQ1 2026
- RevenueEUR 33.51M
- Net incomeEUR 4.26M
- Free cash flowEUR 16.51M
- Gross margin88.5%
Valuation Snapshot
Bullrun's latest valuation model marks GENOVIS AB SE-40 as 40.7% overvalued; latest market cap is EUR 110.59M; P/E is 55.8.
About GENOVIS AB SE-40
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology;
Frequently asked questions
Is GENOVIS AB SE-40 overvalued or undervalued?
Bullrun's valuation model currently marks GENOVIS AB SE-40 as 40.7% overvalued.
What is GENOVIS AB SE-40's market cap?
GENOVIS AB SE-40's market capitalization is EUR 110.59M.
What is GENOVIS AB SE-40's P/E ratio?
GENOVIS AB SE-40's price-to-earnings (P/E) ratio is 55.8.
What does GENOVIS AB SE-40 do?
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1;